Excellergy Advances First-in-Class Allergy Drug Exl-111 Into Phase 1, Backed by Strong Preclinical Data

New updates have been reported about Excellergy.

Excellergy has released new preclinical data on its lead candidate Exl-111 and confirmed that the first subjects have been dosed in the Phase 1 DISARM trial, marking the company’s transition from preclinical to clinical-stage development. Exl-111 is the first allergic Effector Cell Response Inhibitor (ECRI) to reach the clinic, designed to directly disrupt the IgE-driven activation of effector cells that underpins severe allergic disease.

In primate studies, Exl-111 achieved rapid and near-complete removal of receptor-bound IgE from basophils, exceeding 99% clearance, and drove roughly a 95% reduction in FcεRI surface receptor expression, effectively shutting down a key allergic signaling pathway. The candidate was well tolerated at doses up to 100 mg/kg in cynomolgus monkeys, with no evidence of effector-cell activation, systemic toxicity, or local injection-site reactions, supporting a potentially favorable safety margin for human dosing.

Supporting in vitro work using human-donor whole-blood basophils showed that Exl-111 can dissociate receptor-bound IgE in under 24 hours at concentrations expected to be achievable in patients, again without triggering cell activation, reinforcing the mechanistic differentiation from existing anti-IgE therapies. Excellergy’s leadership emphasizes that by rapidly desensitizing effector cells and suppressing IgE binding, Exl-111 could deliver faster onset and more consistent control of allergic inflammation than current standards of care.

The pharmacokinetic and pharmacodynamic package generated in monkeys was used to select starting doses and escalation steps for the Phase 1 DISARM study, underscoring a data-driven approach to early clinical risk management. The Phase 1 trial, initiated in early February, is a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study in about 70 healthy volunteers with no prior anti-IgE exposure, and is designed to characterize safety, tolerability, and early biomarker effects.

External clinical experts note that Excellergy’s ECRI approach, which both strips IgE from its effector-cell receptors and downregulates FcεRI expression without activating those cells, addresses biological limitations that contribute to slow onset, variable response, and non-responder rates with current IgE-targeted drugs. For Excellergy, successful early human data would validate its trifunctional ECRI platform, enhance its strategic positioning in the allergy therapeutics market, and potentially support future financing, partnerships, or pipeline expansion across severe IgE-mediated conditions.

Excellergy, headquartered in Palo Alto and backed by Red Tree Venture Capital, Samsara BioCapital, and Decheng Capital, is building a portfolio of ECRI candidates intended to move beyond traditional anti-IgE approaches by targeting IgE bound directly to effector cells. If the Phase 1 program confirms the preclinical profile, the company could be well placed to progress Exl-111 into patient trials and shape a new competitive segment in the treatment of high-burden allergic diseases.